Nuclear medicine imaging with PET/CT can monitor the effectiveness of immunotherapy treatment for metastatic melanoma and predict patient outcome.

In this way, a patient's therapy can be more effectively tailored to his or her personal response.

Metastatic melanoma is one of the deadliest skin cancers, so the determination of a treatment's effectiveness is essential but can be tricky.

A study featured in the The Journal of Nuclear Medicine demonstrates that 18F-FDG positron emission tomography/computed tomography (PET/CT) can monitor immunotherapy with ipilimumab, a "checkpoint inhibitor" that allows the immune system to attack cancer cells.

"Checkpoint inhibitor therapy is now a standard therapy for metastatic melanoma," explained Wolfgang A. Weber, MD, of Technical University Munich, Germany (formerly of Memorial Sloan Kettering Cancer Center). "However, there were concerns about whether FDG PET/CT could be used to monitor tumour response to this immunotherapy, because inflammatory reactions to the immunotherapy may cause false positive findings. The present study shows that tumour response to checkpoint inhibitor therapy with ipilimumab can be assessed accurately by FDG PET after completion of ipilimumab therapy."

Clinical studies have shown that ipilimumab, when compared with chemotherapy, can significantly improve the survival of patients with metastatic melanoma; however, this is true for only 15 to 20 percent of melanoma patients.

The ability to accurately assess a patient's response to ipilimumab therapy would allow physicians to adjust his or her course of treatment for maximum effectiveness.

To overcome the difficulties of assessing tumour response to ipilimumab and other checkpoint inhibitors, the researchers developed new response criteria.

These new criteria require confirmation of tumour progression on a follow-up scan.

For this retrospective study, 60 patients with metastatic melanoma received FDG PET/CT scans pre- and post-treatment.

Tumour response was assessed by the change in the sum of SULpeak (standard uptake value normalized to lean body mass) of up to 5 lesions (PERCIST5).

A second analysis (PERCIST1) was done of the lesion with the highest SULpeak between the baseline and follow-up scan.

New lesions on PET that appeared suspicious for metastases were considered progressive metabolic disease.

To assess new inflammatory lesions, the team applied their novel immunotherapy-modified PERCIST with a 5-lesion analysis (imPERCIST5).

In imPERCIST5, a new lesion on FDG PET/CT is considered progressive disease only if it increases the sum of SULpeak by more than 20 percent.

The results of the study show that the assessment of tumour response to ipilimumab treatment using PERCIST correlated significantly with the survival of patients with advanced melanoma.

The slight modifications of PERCIST to imPERCIST5 further improved the prognostic value of response assessment by 18F-FDG PET/CT.

Weber pointed out, "FDG PET/CT is routinely used to stage melanoma. The present study suggests that it also can be used to monitor tumour response to ipilimumab therapy and predict the outcome. FDG PET can identify patients with favourable and unfavourable prognoses - leading to therapy escalation (e.g. combination immunotherapy) or de-escalation (e.g. reduced number of therapy cycles)."

In this way, a patient's therapy can be more effectively tailored to his or her personal response.

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.